STOCK TITAN

Oncolytics Biotech Inc - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.

Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.

Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.

Rhea-AI Summary

Oncolytics Biotech reported significant advancements in its pelareorep development programs, particularly in breast and gastrointestinal cancers. The AWARE-1 study suggested blood T cell changes could predict therapy response, enhancing future patient selection. The company also initiated the GOBLET trial in collaboration with Roche, targeting unmet needs in gastrointestinal cancers. Financially, Oncolytics holds approximately $48 million in cash, with a net loss of $4.9 million for Q3 2021, showing improvement from $6.7 million the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) has initiated the phase 1/2 GOBLET trial, dosing the first patient to evaluate the safety and efficacy of the combination of pelareorep and Roche's atezolizumab in gastrointestinal cancers, including metastatic pancreatic, colorectal, and anal cancers. The trial, managed by AIO in Germany, aims to improve patient responses to immune checkpoint inhibitors, addressing the high unmet need in gastrointestinal cancer treatments. The GOBLET study follows promising earlier results, which suggest significant clinical benefits in related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call on November 5, 2021, at 8:00 a.m. ET, to discuss third-quarter financial results and corporate updates. Investors can dial in North America at (888) 664-6383 or internationally at (416) 764-8650. The event will be webcast and archived on the company's Investor Relations page. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at inducing immune responses against various cancers. The company is conducting clinical trials in combination with existing oncology treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences earnings
Rhea-AI Summary

Oncolytics Biotech announced that its partner Adlai Nortye has begun dosing in a clinical trial in China, assessing the safety and efficacy of pelareorep-paclitaxel for advanced breast cancer. This bridging trial aims to enable data inclusion from North American studies in future regulatory submissions. Notably, previous trials indicated a significant survival benefit for patients using pelareorep in combination with paclitaxel. The ongoing collaboration aims to advance pelareorep towards registration in global markets, leveraging China's rapidly growing pharmaceutical landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech announced promising preclinical data highlighting the synergistic effects of pelareorep combined with radiotherapy. Presented at The International Conference on Immunotherapy Radiotherapy Combinations in Paris, the study demonstrated a significant increase in anti-cancer CD8+ T cells and improved survival rates in murine models. The pelareorep-radiotherapy combination outperformed single-agent therapies, indicating its potential for broader application across multiple cancer types. These findings advocate for further research into pelareorep as an effective cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
-
Rhea-AI Summary

Oncolytics Biotech reported significant progress in its clinical trials and financial health for Q2 2021. The AWARE-1 trial achieved its primary endpoint, showing that pelareorep synergizes with checkpoint inhibitors, enhancing survival metrics in breast cancer. Additionally, proof-of-concept data in metastatic pancreatic cancer indicates broad applicability across tumor types. The company maintains a strong financial position with $50.8 million in cash, supporting ongoing trials and strategic partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) announces its participation in the Canaccord Genuity 41st Annual Growth Conference, scheduled for August 10-12, 2021. Dr. Matt Coffey, CEO, will present on August 12 at 1:30 p.m. EDT. The event includes one-on-one investor meetings, and a live webcast will be available on Oncolytics' Investor Relations page, archived for 90 days. The company develops pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. For more information, visit their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) will hold a conference call on August 6, 2021, at 8:00 a.m. ET to discuss the second quarter financial results and corporate updates. The call will be accessible via a toll-free number and will also be available through a webcast for three months. The biotechnology company is focused on developing pelareorep, an immunotherapeutic agent that induces anti-cancer immune responses. This agent is currently in clinical trials for various cancers, including a registration study in metastatic breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences earnings
-
Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 4:30 PM Eastern Daylight Time. Dr. Matt Coffey, President & CEO, will lead the presentation. A live webcast will be available on the company's Investor Relations page and archived for 90 days. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. The company is also engaging in one-on-one investor meetings during the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) announced a promising clinical proof-of-concept for its pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The phase 2 trial, featuring pembrolizumab (KEYTRUDA), showed a 42% disease control rate among patients who had progressed after first-line treatment. The results will be presented at the ASCO Annual Meeting in June 2021. Key findings highlight enhanced T cell activation and well-tolerated treatment. Oncolytics plans to further develop this therapy in collaboration with Roche through the GOBLET study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.13%
Tags
none
Oncolytics Biotech Inc

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

48.58M
82.87M
4.35%
1.62%
3.44%
Biotechnology
Healthcare
Link
Canada
Calgary